Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
Second generation antipsychotic medication
adolescents
weight gain
youth mental health
Journal
Early intervention in psychiatry
ISSN: 1751-7893
Titre abrégé: Early Interv Psychiatry
Pays: Australia
ID NLM: 101320027
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
07
04
2020
received:
07
01
2020
accepted:
24
05
2020
pubmed:
28
7
2020
medline:
11
3
2022
entrez:
28
7
2020
Statut:
ppublish
Résumé
Long-acting injectable (LAI)antipsychotics are often used in psychosis to assist with medication compliance and relapse prevention, although the weight gain and metabolic effects in young people are yet to be examined. This study examined the long-term effects of aripiprazole and paliperidone in LAI formulation on weight gain and metabolic parameters in young people with early episode psychosis. Weight gain and other metabolic effects of aripiprazole and paliperidone in LAI formulation were examined in 59 young people with early episode psychosis over a 12-month period. Changes in outcome measurements were examined at baseline and 3 monthly intervals. The results showed that both aripiprazole and paliperidone were associated with time-dependent increases in weight. At 12 months, weight increased by an average of 7% (6 kg) with both aripiprazole and paliperidone relative to the baseline, and the percentage of overweight or obese people increased from 33% to 60%. There was no advantage of aripiprazole compared to paliperidone with regards to weight change, although aripiprazole was associated with lower triglycerides and prolactin levels. Both LAI medications were associated with substantial weight increases over time. These results build on emerging evidence showing that aripiprazole is not weight neutral in young people. Our recommendation is that weight-management programs should be offered from the start of medication initiation.
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Aripiprazole
82VFR53I78
Paliperidone Palmitate
R8P8USM8FR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-793Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Caccia, S. (2013). Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatric Drugs, 15, 217-233.
Casey, D., Haupt, D., Newcomer, J., Henderson, D., Sernyak, M., Davidson, M., … Hennekens, C. (2004). Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry, 65, 4-18.
Catts, S. V., & O'Toole, B. I. (2016). The treatment of schizophrenia: Can we raise the standard of care? Australian and New Zealand Journal of Psychiatry, 50(12), 1128-1138.
Chang, J. S., Ahn, Y. M., Park, H. J., Lee, K. Y., Kim, S. H., Kang, U. G., & Kim, Y. S. (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomised, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 69(5), 720-731.
Chee, G., Wynaden, D., & Heslop, K. (2019). The physical health of young people experiencing first-episode psychosis: Mental health consumers' experiences. International Journal of Mental Health Nursing, 28(1), 330-338.
Citrome, L. (2007). Paliperidone: quo vadis? International Journal of Clinical Practice, 61(4), 653-662.
Cohen, J. (1988). Statistical power analysis for the behaviors science (2nd ed.). Hillsdale, New Jersey: Lawrence Erlbaum Associates Publishers.
Correll, C. U., & Carlson, H. E. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45(7), 771-791.
Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J., & Malhotra, A. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association, 302, 1765-1773.
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007). Efficacy, safety and early response of Paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomised, placebo-controlled study. Schizophrenia Research, 93(2007), 117-130.
De Hert, M., Cohen, D., Bobes, J., Cetkovich-Bakmas, M., Leucht, S., Ndetei, D. M., … Gautam, S. (2011). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 10(2), 138-151.
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26(3), 144-158.
Dixon, J. B. (2010). The effect of obesity on health outcomes. Molecular and Cellular Endocrinology, 316(2), 104-108.
Fakhoury, W. K., Wright, D., & Wallace, M. (2001). Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. International Clinical Psychopharmacology, 16(3), 153-162.
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., … Stubbs, B. (2019). The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry, 6(8), 675-712.
Foley, D., Mackinnon, A., Watts, G., Shaw, J., Magliano, D., Castle, D., … Galletly, C. (2013). Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. PLoS One, 8(12), e82606.
Fraguas, D., Merchán-Naranjo, J., Laita, P., Parellada, M., Moreno, D., Ruiz-Sancho, A., … Arango, C. (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry, 69(7), 1166-1175.
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., … Tran, N. (2016). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 50(5), 410-472.
Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: a critical overview. CMAJ, 172(13), 1703-1711.
Godin, O., Leboyer, M., Schürhoff, F., Llorca, P., Boyer, L., Andre, M., et al. (2018). Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. Journal of Clinical Psychiatry, 79, 6.
Goldman, H. H., Skodol, A. E., & Lave, T. R. (1992). Revising axis V for DSM-IV: A review of measures of social functioning. American Journal of Psychiatry, 149, 1148-1156.
Gómez-Revuelta, M., Pelayo-Terán, J. M., Juncal-Ruiz, M., Ortiz-García de la Foz, V., Vázquez-Bourgon, J., González-Pinto, A., & Crespo-Facorro, B. (2018). Long-term antipsychotic effectiveness in first episode of psychosis: A 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. International Journal of Neuropsychopharmacology, 21(12), 1090-1101.
Harrison, J. N., Cluxton-Keller, F., & Gross, D. (2012). Antipsychotic medication prescribing trends in children and adolescents. Journal of Pediatric Health Care, 26(2), 139-145.
Kang, N. I., Koo, B. H., Kim, S. W., Kim, J. H., Nam, B., Lee, B., … Hahn, S. W. (2016). Efficacy and tolerability of paliperidone extended-release in the treatment of first-episode psychosis: An eight-week, open-label, multicenter trial. Clinical Psychopharmacology and Neuroscience, 14(3), 261-269.
Kessler, R. C., Andrews, G., Colpe, L. J., Hiripi, E., Mroczek, D. K., Normand, S. L., … Zaslavsky, A. M. (2002). Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychological Medicine, 32(6), 959-976.
Krill, R. A., & Kumra, S. (2014). Metabolic consequences of second-generation antipsychotics in youth: Appropriate monitoring and clinical management. Adolescent Health and Medical Therapeutics, 5, 171.
Kwan, B., Rickwood, D. J., & Telford, N. R. (2018). Development and validation of MyLifeTracker: a routine outcome measure for youth mental health. Psychology Research Behaviour Management, 11, 67-77.
Malla, A., Mustafa, S., Rho, A., Abadi, S., Lepage, M., & Joober, R. (2016). Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study. Schizophrenia Research, 174, 120-125.
Manu, P., Khan, S., Radhakrishnan, R., Russ, M. J., Kane, J. M., & Correll, C. U. (2014). Body mass index identified as an independent predictor of psychiatric readmission. Journal of Clinical Psychiatry, 75, 573-577.
Marder, S., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007). Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week randomized, placebo-controlled study. Biological Psychiatry, 62, 1363-1370.
McClellan, J., & Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy Child Adolescent Psychiatry, 52, 976-990.
McQuade, R. D., Stock, E., Marcus, R., Jody, D., Gharbia, N. A., Vanveggel, S., … Carson, W. H. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry, 65(Suppl 18), 47-56.
Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia bulletin, 39(2), 295-305.
Nasrallah, H. (2003). A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 28, 83-96.
Nasarallah, H. A. (2007). The case for long-acting antipsychotic agents in the post CATIE-era. Acta Psychiatrica Scandavica, 115, 260-267.
Newcomer, J. W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry, 68(Suppl 1), 20-27.
Olfson, M., King, M., & Schoenbaum, M. (2015). Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 72(9), 867-874.
Overall, J. E., & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports, 10(3), 799-812.
Pan, A., Keum, N., Okereke, L., Sun, Q., Kivimaki, M., Rubin, R., & Hu, F. (2012). Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care, 35, 1171-1180.
Pringsheim, T., Panagiotopoulos, M. D., Davison, J., et al. (2011). Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatric Child Health, 16(9), 581-589.
Robinson, D. G., Gallego, J. A., John, M., Petrides, G., Hassoun, Y., Zhang, J., … Kellner, C. (2015). A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophrenia Bulletin, 41(6), 1227-1236.
Rodday, A., Parsons, S., Mankiw, C., Correll, C., Robb, A., Zima, B., … Leslie, L. (2015). Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics. Journal of Child and Adolescent Psychopharmacology, 25, 51-361.
Shiers, D., Jones, P. B., & Field, S. (2009). Early intervention in psychosis: keeping the body in mind. British Journal of General Practice, 59, 395-396.
Si, T., Tan, Q., Zhang, K., Wang, Y., & Rui, Q. (2015). An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis. Neuropsychiatric Disorder and Treatment, 11, 87.
Sliwa, J. K., Bossie, C. A., Fu, D., Turkoz, I., & Alphs, L. (2012). Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disorder and Treatment, 8, 375-385.
Snigdha, S., Thumbi, C., Reynolds, G. P., & Neill, J. C. (2008). Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. Journal of Psychopharmacology, 22(5), 567-571.
Stanley, S. H., & Laugharne, J. D. (2011). Clinical guidelines for the physical care of mental health consumers: a comprehensive assessment and monitoring package for mental health and primary care clinicians. Australian and New Zealand Journal of Psychiatry, 45, 824-829.
Stigler, K. A., Potenza, M. N., Posey, D. J., & McDougle, C. J. (2004). Weight gain associated with atypical antipsychotics use in children and adolescents: Prevalence, clinical relevance, and management. Paediatric Drugs, 6(1), 33-44.
Tek, C., Kucukgoncu, S., Guloksuz, S., Woods, S., Srihari, V., & Annamalai, A. (2016). Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interventions in Psychiatry, 10(3), 193-202.
Vázquez-Bourgon, J., Pérez-Iglesias, R., de la Foz, V. O. G., Pinilla, P. S., Martínez, Á. D., & Crespo-Facorro, B. (2018). Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology, 235(1), 245-255.
Zhang, Y., & Dai, G. (2012). Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first episode schizophrenia through 52 weeks follow-up in China. Human Psychopharmacology, 27, 605-614.